Viking Therapeutics Inc (NASDAQ: VKTX) reported new clinical data for its oral obesity drug – sending shares sharply lower as investors balked at tolerability concerns and dropout rates. The Phase 2 trial showed promising weight loss results, but a 28% discontinuation rate in the first three months triggered fears about…
A brutal rotation out of big tech sent a shockwave from Wall Street across the Pacific, setting Asian markets…
In a significant development for weight management, the Food and Drug Administration (FDA) announced Wednesday its approval of the…
A nasty summer surprise has dealt a significant blow to the UK economy, as official data revealed on Wednesday.…
Shares of popular Labubu doll maker Pop Mart touched record highs on Wednesday following strong earnings results which saw…
The fragile optimism that had buoyed European markets has been shattered, as a nasty inflation surprise from the UK…
The US economy is sending mixed signals. Growth has slowed, job creation has weakened, yet prices keep rising in…
The announcement from the White House on Monday was bold, hopeful, and seemingly unanimous: the next step toward peace…
As traditional real estate continues to struggle with climbing back into the growth territory in 2025, a quieter transformation…